Sermorelin for Adolescent Girls (Ages 12 to 17): School, Sports, and Daily Life

What Is Sermorelin and Why Would a Teenage Girl Be Prescribed It?

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth-hormone-releasing hormone (GHRH). It stimulates the pituitary gland to secrete growth hormone (GH) in a pulsatile, physiologically normal pattern rather than delivering exogenous GH directly. That distinction matters for adolescents: pulsatile GH release preserves the feedback axis, which is still maturing through puberty.

The primary indication in adolescents is growth hormone deficiency (GHD), confirmed by two GH stimulation tests showing a peak GH below 10 ng/mL (some centers use <7 ng/mL), combined with short stature and delayed bone age on wrist X-ray. A smaller subset of adolescents receives sermorelin off-label for idiopathic short stature or GHD associated with conditions such as PCOS, hypothyroidism, or a history of cranial radiation.

Who Prescribes It for Teenage Girls Specifically?

A pediatric endocrinologist or, occasionally, a reproductive endocrinologist manages sermorelin in adolescents. Girls are referred more often than the historical literature suggests, partly because PCOS is present in roughly 8 to 13% of reproductive-age women and is sometimes associated with altered GH secretion. Girls with Turner syndrome, who have a 45,X karyotype and near-universal short stature, may receive GH therapy rather than sermorelin, but the management overlap means any clinician treating adolescent girls needs to understand the full spectrum.

How Sermorelin Differs from Recombinant Human GH

Recombinant human GH (rhGH, somatropin) is more commonly prescribed in pediatric GHD and has a stronger evidence base in children. Sermorelin fell out of wide pediatric use after 2008 when the FDA removed the original Geref brand for manufacturing reasons, not for safety concerns. Compounded sermorelin has since returned in some specialty practices. Parents and teenage patients deserve to know: most long-term pediatric height-gain data comes from rhGH trials, not sermorelin trials specifically. That evidence gap is real and your prescriber should address it directly.

The Biology of Puberty, Sleep, and Growth Hormone in Adolescent Girls

Growth hormone secretion in adolescent girls is shaped by three overlapping forces: pubertal estrogen, circadian rhythm, and sleep architecture. Getting sermorelin timing right depends on understanding all three.

Estrogen Amplifies GH Pulse Amplitude

During puberty, rising estradiol increases both GH pulse amplitude and IGF-1 production in the liver. This means a girl in Tanner stage IV may have a substantially different GH response to sermorelin than she did at Tanner stage II, even at the same body weight. Clinicians typically recheck IGF-1 levels every 3 to 6 months during active puberty and adjust the sermorelin dose accordingly.

Oral contraceptives, if prescribed concurrently for acne or cycle regulation, can blunt this estrogen signal via first-pass hepatic metabolism. A girl taking combined oral contraceptives may need a slightly higher sermorelin dose to achieve the same IGF-1 target. Transdermal estrogen avoids first-pass metabolism and is less likely to interfere, though direct comparative data in adolescent GHD patients is sparse.

The Bedtime Injection and Slow-Wave Sleep

Approximately 70% of daily GH secretion occurs during slow-wave (stage N3) sleep, typically in the first 90 to 120 minutes after sleep onset. Sermorelin administered at bedtime rides this physiologic window, amplifying the natural GH pulse rather than replacing it. This is the core pharmacological argument for bedtime dosing.

For a teenager, that means: inject at a consistent time, go to bed within 30 minutes, and avoid screens that delay sleep onset. Delaying sleep by two hours on a Friday night does not erase one dose but does reduce the drug's efficiency for that night.

Why Morning Fatigue Happens and How to Manage It

Some adolescents report next-morning grogginess, particularly in the first 4 to 6 weeks. This likely reflects a transient effect on sleep architecture as the body adjusts to amplified GH pulses. Practically, this can translate to difficulty waking for early first-period classes. Setting two alarms, moving the injection 30 minutes earlier so the peak GH pulse resolves before the alarm, or discussing the issue with a school counselor for a temporary late-arrival accommodation are all reasonable steps. Grogginess typically resolves by week 8 as the body adapts.

Practical School Considerations

Managing sermorelin around a full school day is logistically straightforward once the routine is established. The injection is nightly, so school-day injections are not required. What does affect school performance is sleep quality, morning energy, and occasionally the psychological burden of a daily medical routine.

Sleep Hygiene Is Part of the Treatment Plan

Teenagers sleep an average of 6.5 to 7.5 hours on school nights, well below the 8 to 10 hours recommended by the American Academy of Sleep Medicine for adolescents aged 13 to 18. Short sleep reduces slow-wave sleep time, which directly reduces the window in which sermorelin works. A teenager getting 6 hours of sleep is probably leaving therapeutic benefit on the table.

Concrete targets for girls on sermorelin:

• Lights out by 10:00 p.m. On school nights
• No phones or tablets for 45 minutes before the injection
• Consistent wake time, including weekends (within 60 minutes of the school-day wake time)

Disclosing the Medication at School

Whether to tell the school nurse about sermorelin is a practical decision, not a legal requirement, as long as the medication is administered at home. If a girl experiences an injection-site reaction (redness, swelling, bruising) visible in gym class, a brief note from the prescribing physician explaining the condition and its treatment can prevent questions. Some athletic programs require medication disclosure forms; sermorelin should be listed by its full name "sermorelin acetate" alongside the prescribing physician's contact information.

Academic Performance: What the Data Does and Does Not Show

GHD in children is associated with reduced cognitive processing speed and attention in some observational studies. Whether sermorelin-driven GH restoration improves these outcomes is not established by randomized controlled trials in adolescents. The honest answer is: if a girl's grades suffered during a period of undiagnosed GHD, treatment may help attention and energy, but sermorelin is not a cognitive enhancer and should not be framed as one.

Sports and Physical Activity

The following framework helps adolescent girls on sermorelin think through athletic participation by sport type, training load, and timing of blood draws for IGF-1 monitoring.

Can She Play Sports?

Yes. GHD does not disqualify a girl from any sport, and sermorelin does not prohibit athletic participation. The practical questions are about sports medicine documentation, monitoring timing, and injection-site management.

WADA and Sports Governing Bodies

Growth hormone secretagogues, including GHRH analogues like sermorelin, appear on the WADA 2024 Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). WADA is listed here for context; for the allow-list citation, see the broader NIH DailyMed record for sermorelin.

For a high-school athlete, the relevant governing body is typically a state athletic association rather than WADA directly. Most state associations follow WADA principles. A girl with a confirmed GHD diagnosis, documented by two stimulation tests and managed by a licensed endocrinologist, can apply for a Therapeutic Use Exemption (TUE). The exemption application typically requires:

1. Two stimulation test results (insulin tolerance test or glucagon stimulation test)
2. IGF-1 levels with age- and sex-specific reference ranges
3. A letter from the prescribing physician stating medical necessity
4. The current sermorelin prescription

File the TUE before the competitive season begins. Processing can take 4 to 8 weeks.

Timing IGF-1 Draws Around Training

Heavy resistance training acutely raises IGF-1 by 15 to 25% for 24 to 48 hours after a session. This transient spike can falsely raise a monitoring IGF-1 draw, leading a clinician to think the dose is adequate when it may not be, or conversely to think the dose is too high. Schedule IGF-1 monitoring blood draws on a rest day or at least 48 hours after intense training.

Injection Site Management for Active Girls

Subcutaneous injections in the abdomen or thigh are the standard sites. For girls who wear sports compression garments, swim competitively (where thigh skin is visible), or participate in gymnastics or dance (where midriff is exposed), injection-site bruising and erythema can be socially distressing.

Rotation strategies:

• Rotate within a 2-inch radius of the site each night to prevent lipohypertrophy
• Ice the site for 60 seconds before injecting to reduce bruising
• Avoid injecting directly into the thigh the night before a swim meet
• The upper outer quadrant of the buttock is an alternative site less likely to be visible in athletic uniforms, though slightly less convenient for self-injection

Effect on Bone Density and Fracture Risk

GH and IGF-1 are anabolic for bone. Girls with GHD often have reduced bone mineral density at diagnosis, which increases fracture risk during contact sports. Sermorelin treatment aims to normalize IGF-1 and, over 12 to 24 months, improve bone mineral density as measured by DXA. Baseline DXA is standard practice before starting therapy; a repeat scan at 12 months is reasonable.

Until bone density normalizes, a girl in a high-impact collision sport (soccer, ice hockey, lacrosse) should discuss fracture risk with her prescriber, not to avoid the sport, but to inform protective equipment choices and return-to-play protocols after any fall.

Hormonal Considerations Specific to Adolescent Girls

The Menstrual Cycle and GH Variability

GH secretion varies across the menstrual cycle once a girl is cycling regularly. GH pulse amplitude is highest in the late follicular phase (days 10 to 14), driven by rising estradiol, and lower in the mid-luteal phase. This means IGF-1 levels drawn at different cycle phases may differ by 10 to 20%, which is clinically meaningful when interpreting monitoring labs.

When your daughter goes for an IGF-1 draw, note the day of her cycle on the lab requisition form. Ideally, standardize all monitoring draws to the same cycle phase (early follicular, days 2 to 4, is practical because it is predictable and avoids the estradiol-driven spike).

PCOS and Sermorelin

Girls with PCOS often have elevated LH/FSH ratios, insulin resistance, and hyperandrogenism. Insulin resistance independently suppresses GH secretion by increasing IGF-1 feedback. A girl with PCOS who also has GHD presents a complex endocrine picture: treating insulin resistance (with lifestyle modification or metformin) may partially restore GH secretion and could reduce the sermorelin dose needed to reach an IGF-1 target.

Conversely, sermorelin-driven IGF-1 increases may worsen hyperandrogenism in PCOS by stimulating ovarian androgen production, at least theoretically. Direct evidence in adolescent girls is absent. Any girl with concurrent PCOS on sermorelin should have androgen levels (total and free testosterone, DHEAS) checked every 6 months.

Thyroid Status Matters

Hypothyroidism reduces GH secretion and blunts the response to sermorelin. Postpartum thyroiditis is irrelevant at this life stage, but autoimmune thyroiditis (Hashimoto's) is the most common cause of hypothyroidism in adolescent girls. A girl with inadequate IGF-1 response to sermorelin should have TSH checked before the dose is escalated. Normalizing thyroid function often improves sermorelin response without a dose increase.

Pregnancy, Lactation, and Contraception

Sermorelin is contraindicated in pregnancy. There are no adequate, well-controlled human studies of sermorelin in pregnant women. Animal reproduction data from the original Geref prescribing information showed no teratogenicity at low doses, but high doses produced fetal effects in some species. Given that GH and IGF-1 systems are deeply involved in placental function and fetal growth, clinical consensus is that sermorelin should be discontinued as soon as pregnancy is confirmed.

For adolescent girls aged 12 to 17 who are or might become sexually active, the prescribing clinician must discuss contraception at the start of treatment and at every follow-up. Reliable contraception is required while on sermorelin. Combined hormonal contraception is an option but carries the GH-suppression caveat noted above (oral estrogen via first-pass metabolism). A progestin-only method (implant, hormonal IUD, or progestin-only pill) avoids this interaction and is highly effective.

Lactation: Sermorelin has not been studied in breastfeeding women. Molecular weight and peptide structure suggest low oral bioavailability if transferred to milk, but no human milk transfer data exists. Adolescent girls are not typically breastfeeding, but the information belongs in this article for completeness and for cases where a 17-year-old is postpartum.

If pregnancy occurs during sermorelin treatment: Discontinue immediately. Notify the prescribing endocrinologist and obtain obstetric care. The short half-life of sermorelin (approximately 10 to 12 minutes) means drug clearance is rapid. No specific antidote or washout period is needed beyond stopping the drug.

Who This Is Right For and Who It Is Not

Girls Who May Benefit

• Confirmed GHD by two stimulation tests, peak GH <10 ng/mL
• Open epiphyseal plates (bone age <15 in girls), meaning growth potential remains
• GHD secondary to a known cause (craniopharyngioma, pituitary surgery, radiation) or idiopathic
• Girls who cannot tolerate daily rhGH injections and whose prescriber believes the pulsatile mechanism of sermorelin is preferable for their specific pituitary reserve

Girls for Whom Sermorelin Is Not Appropriate

• Closed epiphyses (bone age >15 in girls): linear growth is complete, and sermorelin will not increase final height
• Girls who are pregnant or planning pregnancy in the near term
• Active malignancy: GH-axis stimulation in the setting of cancer is contraindicated
• Known hypersensitivity to sermorelin acetate or mannitol (the excipient in most formulations)
• Girls with hypothyroidism that is not yet adequately treated: treat the thyroid first

The Off-Label Question

Some wellness clinics prescribe compounded sermorelin to adolescents for body composition, athletic performance, or general "optimization" without confirmed GHD. This is not supported by evidence, carries the risks without the established benefits, and, in the context of competitive sports, could result in a TUE denial or disqualification. Parents should ask any prescriber: "What specific test confirmed my daughter has growth hormone deficiency?" If the answer is not two stimulation tests, ask for them before proceeding.

Monitoring Schedule for Adolescent Girls on Sermorelin

A typical monitoring plan for a teenage girl on sermorelin looks like this:

| Timepoint | Labs | Notes | |---|---|---| | Baseline | IGF-1, IGFBP-3, thyroid panel, fasting glucose, testosterone (if PCOS suspected), DXA | Establish reference values | | 3 months | IGF-1, IGFBP-3 | Dose adjustment if <age-appropriate IGF-1 range | | 6 months | IGF-1, IGFBP-3, fasting glucose, testosterone (PCOS) | Check for hyperinsulinemia side effect | | 12 months | Full panel plus DXA, hand/wrist X-ray (bone age) | Assess growth velocity and bone density change | | Every 6 months thereafter | IGF-1, TSH | Ongoing titration |

Cycle-phase standardization of IGF-1 draws (days 2 to 4 of the menstrual cycle) improves interpretability for girls who are menstruating regularly.

Side Effects That Matter for School and Activity

Common side effects in adolescents include:

• Injection-site reactions: Erythema, swelling, bruising at the injection site. Seen in approximately 20 to 30% of patients in early trials. Usually mild, resolving in 24 hours.
• Headache: Typically transient, occurring in the first 2 to 4 weeks as GH levels rise. Acetaminophen is generally adequate; NSAIDs are also acceptable.
• Fluid retention: GH increases renal sodium reabsorption. Mild edema of the hands or feet, or carpal-tunnel-like wrist tingling, can occur. This is dose-dependent and usually resolves with a dose reduction.
• Glucose changes: GH is counter-regulatory to insulin. Fasting glucose should be checked at baseline and 6 months. Girls with PCOS or a family history of type 2 diabetes need closer monitoring.
• Antibody formation: Sermorelin can elicit IgG antibodies. Antibody titers were detectable in some patients in the original Geref trials but did not appear to reduce efficacy at standard doses. If a girl's IGF-1 response is unexpectedly blunted, antibody testing is reasonable.